ACG: Acute IBD Flares Respond to Infliximab (CME/CE)
SAN ANTONIO (MedPage Today) — Hospitalized patients with exacerbations of Crohn’s disease or ulcerative colitis who are naive to anti-tumor necrosis factor agents did well when given infliximab (Remicade), researchers found.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com